Mike Hollan

The energy component—and cost—associated with artificial intelligence should not be overlooked in all the excitement.

Naumovic discusses the impact that a lack of messaging can have a community.

A change in political power is altering how companies are strategizing around the IRA.

Many people are still uninformed about both the short- and long-term impacts of the virus.

The Phesi CEO discusses his company’s recent analysis of the most studied diseases in the world.

Biljana Naumovic discusses how a new study attempted to bring in patients from underserved communities.

Biljana Naumovic discusses the importance of finding ways to reach out to underserved communites.

New technology is creating new opportunities but is also causing new complications.

Susan Cantrell responds to the tariffs on China, Canada, and Mexico.

Biljana Naumovic of Johnson & Johnson discusses the unique fashion show and how it's raising awareness for prostate cancer.

Hiroyuki Okuzawa will step into the role starting in April.

President Trump’s tariffs will include imported pharmaceuticals, among other items that will impact the industry.

Senators Durbin and Grassley proposed the new regulations for direct-to-consumer pharma advertising.

The survey shows voters, regardless of party affiliation, still support vaccines and are concerned about the reduction in vaccine rates.

The two companies will combine existing assets in order to find new connections and opportunities.

The new app provides user with more features, including an AI-powered search, than the pharmacy’s previous app.

Paul Howe, chief commercial officer at Protega Pharma, discusses recent rule changes and how the industry is impacted by them.

The senior vice president at Lilly Immunology Development discusses recent developments with Omvoh.

Paul Howe, chief commercial officer at Protega Pharma, discusses how regulatory agencies are updating their policies based on the presence of abuse-deterrent medications.

The health-tech company is teaming up with Vitable and MARPAI on the project.

The deal allows for sugemalimab to be commercialized across 10 Latin America countries.

Veeva’s vice president of commercial strategy discusses how pharma companies streamlining their processes with a single goal in mind can improve their relationships with customers.

Paul Howe, chief commercial officer at Protega, discusses efforts to combine high tech solutions with pain-management medications.

The company’s previous officer has stepped down from the role.

Ash Shehata from KPMG discusses how artificial technology has a lot to prove, although investors still see a lot of potential in it.

The two organizations will produce educational materials about the medicine and its importance for people living with type 1 and 2 diabetes.

This is the latest AI tool from the company to provide insights from public sources.

As investors react to an ever-changing political climate, Ash Shehata from KPMG explains what factors they're paying attention to.

Ash Shehata from KPMG discusses how investors are feeling about the pharma and life sciences industry heading into 2025.

The EY executive discusses trends in this sector and what he expects to see in the coming year.